adoptive cellular therapy

BIOLOGICAL2 trials

Sponsors

Kyoto Prefectural University of Medicine, Division of Gastroenterology and Hepatology, Cell Medica Ltd

Conditions

Cytomegalovirus InfectionHepatocellular carcinoma

Phase 2

Efficacy of adoptive cellular therapy with naive rich T cell on recurrence after curative radiofrequency ablation for primary hepatocellular carcinoma (Phase 2 study)

Active, not recruitingJPRN-UMIN000003861

Kyoto Prefectural University of Medicine, Division of Gastroenterology and HepatologyHepatocellular carcinoma

Start: 2010-07-01Target: 25Updated: 2026-06-29

Phase 3

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

CompletedNCT01077908

Cell Medica LtdCytomegalovirus Infection

Start: 2008-07-31End: 2014-10-31Updated: 2018-01-25

Related Papers

Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study

Frontiers in Immunology2023-10-306 citations